|
KMID : 0620920220540040531
|
|
Experimental & Molecular Medicine
2022 Volume.54 No. 4 p.531 ~ p.541
|
|
|
An aptamer agonist of the insulin receptor acts as a positive or negative allosteric modulator, depending on its concentration
|
|
Yunn Na-Oh
Lee Ji-Min
Lee Hye-Sun
Oh Eun-Ju
Park Man-Geun
Park Seong-Eun
Jin Seo-Yeon
Shin Eui-Su
Lee Jo-Woon-Yi
Kim Youn-Dong
Bae Sun-Sik
Ryu Sung-Ho
|
|
|
Abstract
|
|
|
|
Aptamers are widely used as binders that interact with targets with high affinity or as inhibitors of the function of target molecules. However, they have also been used to modulate target protein function, which they achieve by activating the target or stabilizing its conformation. Here, we report a unique aptamer modulator of the insulin receptor (IR), IR-A62. Alone, IR-A62 acts as a biased agonist that preferentially induces Y1150 monophosphorylation of IR. However, when administered alongside insulin, IR-A62 shows variable binding cooperativity depending on the ligand concentration. At low concentrations, IR-A62 acts as a positive allosteric modulator (PAM) agonist that enhances insulin binding, but at high concentrations, it acts as a negative allosteric modulator (NAM) agonist that competes with insulin for IR. Moreover, the concentration of insulin affects the binding of IR-A62 to IR. Finally, the subcutaneous administration of IR-A62 to diabetic mice reduces blood glucose levels with a longer-lasting effect than insulin administration. These findings imply that aptamers can elicit various responses from receptors beyond those of a simple agonist or inhibitor. We expect further studies of IR-A62 to help reveal the mechanism of IR activation and greatly expand the range of therapeutic applications of aptamers.
|
|
|
KEYWORD
|
|
|
Cell signalling, DNA and RNA
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|